What is Allogene Therapeutics, Inc. Common Stock's Market Cap?

Allogene Therapeutics, Inc. Common Stock's Market Cap is $608.1M, based on as-reported figures from SEC (XBRL) filings.

What is Allogene Therapeutics, Inc. Common Stock's Enterprise Value?

Allogene Therapeutics, Inc. Common Stock's Enterprise Value is $569.4M, based on as-reported figures from SEC (XBRL) filings.

What is Allogene Therapeutics, Inc. Common Stock's Price / Sales?

Allogene Therapeutics, Inc. Common Stock's Price / Sales is 131.0×, based on as-reported figures from SEC (XBRL) filings.

What is Allogene Therapeutics, Inc. Common Stock's EV / Revenue?

Allogene Therapeutics, Inc. Common Stock's EV / Revenue is 122.7×, based on as-reported figures from SEC (XBRL) filings.

What is Allogene Therapeutics, Inc. Common Stock's EV / EBITDA?

Allogene Therapeutics, Inc. Common Stock's EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.

What is Allogene Therapeutics, Inc. Common Stock's Revenue (TTM)?

Allogene Therapeutics, Inc. Common Stock's Revenue (TTM) is $4.6M, based on as-reported figures from SEC (XBRL) filings.

What is Allogene Therapeutics, Inc. Common Stock's Net Income (TTM)?

Allogene Therapeutics, Inc. Common Stock's Net Income (TTM) is -$165.5M, based on as-reported figures from SEC (XBRL) filings.

What is Allogene Therapeutics, Inc. Common Stock's EBITDA?

Allogene Therapeutics, Inc. Common Stock's EBITDA is -$168.6M, based on as-reported figures from SEC (XBRL) filings.

What is Allogene Therapeutics, Inc. Common Stock's Diluted EPS (TTM)?

Allogene Therapeutics, Inc. Common Stock's Diluted EPS (TTM) is -0.48, based on as-reported figures from SEC (XBRL) filings.

What is Allogene Therapeutics, Inc. Common Stock's EBITDA Margin?

Allogene Therapeutics, Inc. Common Stock's EBITDA Margin is -3634.7%, based on as-reported figures from SEC (XBRL) filings.

Allogene Therapeutics, Inc. Common Stock (ALLO) Financial Statements

Allogene Therapeutics, Inc. Common Stock

SIC 2836 · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

FIGI BBG00KHRRDY2

XNAS · usd

1.76▲ 0.03 (1.73%)

As of 2026-09-10

Valuation

Market Cap

Enterprise Value

Trailing P/E—

Price / Sales

EV / Revenue

EV / EBITDA

Financial Highlights

Revenue (TTM)

Net Income (TTM)

EBITDA

Diluted EPS (TTM)

EBITDA Margin

Net Debt

Trading Information

Previous Close1.73

Day's Range1.70 – 1.78

52-Week Range1.04 – 4.46

Volume5.4M

Avg Volume5.3M

Share Statistics

Shares Outstanding

Employees152

ExchangeXNAS

Listed2018-10-11

Share count as of August 10, 2026

ViewDetail

Period

Loading Income Statement…

Key questions about Allogene Therapeutics, Inc. Common Stock (ALLO)

What is Allogene Therapeutics, Inc. Common Stock's Market Cap?: Allogene Therapeutics, Inc. Common Stock's Market Cap is $608.1M, based on as-reported figures from SEC (XBRL) filings.
What is Allogene Therapeutics, Inc. Common Stock's Enterprise Value?: Allogene Therapeutics, Inc. Common Stock's Enterprise Value is $569.4M, based on as-reported figures from SEC (XBRL) filings.
What is Allogene Therapeutics, Inc. Common Stock's Price / Sales?: Allogene Therapeutics, Inc. Common Stock's Price / Sales is 131.0×, based on as-reported figures from SEC (XBRL) filings.
What is Allogene Therapeutics, Inc. Common Stock's EV / Revenue?: Allogene Therapeutics, Inc. Common Stock's EV / Revenue is 122.7×, based on as-reported figures from SEC (XBRL) filings.
What is Allogene Therapeutics, Inc. Common Stock's EV / EBITDA?: Allogene Therapeutics, Inc. Common Stock's EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is Allogene Therapeutics, Inc. Common Stock's Revenue (TTM)?: Allogene Therapeutics, Inc. Common Stock's Revenue (TTM) is $4.6M, based on as-reported figures from SEC (XBRL) filings.
What is Allogene Therapeutics, Inc. Common Stock's Net Income (TTM)?: Allogene Therapeutics, Inc. Common Stock's Net Income (TTM) is -$165.5M, based on as-reported figures from SEC (XBRL) filings.
What is Allogene Therapeutics, Inc. Common Stock's EBITDA?: Allogene Therapeutics, Inc. Common Stock's EBITDA is -$168.6M, based on as-reported figures from SEC (XBRL) filings.
What is Allogene Therapeutics, Inc. Common Stock's Diluted EPS (TTM)?: Allogene Therapeutics, Inc. Common Stock's Diluted EPS (TTM) is -0.48, based on as-reported figures from SEC (XBRL) filings.
What is Allogene Therapeutics, Inc. Common Stock's EBITDA Margin?: Allogene Therapeutics, Inc. Common Stock's EBITDA Margin is -3634.7%, based on as-reported figures from SEC (XBRL) filings.